Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sex differences in trauma exposure and symptomatology in trauma-affected refugees

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of ketogenic diet and ketone monoester supplement on acute alcohol withdrawal symptoms in male mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Schizophrenia is associated with a lowered bone mineral density. The antidiabetic and body weight lowering glucagon-like peptide-1 receptor agonist liraglutide has shown to mitigate overweight and impaired glucose tolerance associated with olanzapine and clozapine. As liraglutide has been proposed to affect bone metabolism, we evaluated the effect of liraglutide on bone turnover markers (BTM) in patients with prediabetes and schizophrenia treated with olanzapine or clozapine. Patients diagnosed with a schizophrenia spectrum disorder treated with the antipsychotic compounds clozapine and/or olanzapine, having prediabetes and a BMI above 27 kg/m2 were randomized to 16 weeks of treatment with liraglutide or placebo. Fasting state serum sampled in the morning from patients (n=78) were analysed for the BTM collagen type 1 C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP). After 16 weeks of treatment, no significant changes of neither P1NP nor CTX were observed when comparing liraglutide to placebo. No association between changes of bone turnover markers and change of body weight were found in the group treated with liraglutide. In conclusion, no treatment effect on CTX nor P1NP was observed, and thus, this study does not raise any concerns in patients with schizophrenia and prediabetes treated with liraglutide regarding bone-related adverse effects.

TidsskriftPsychiatry Research
Sider (fra-til)113670
StatusUdgivet - feb. 2021

Bibliografisk note

Copyright © 2020. Published by Elsevier B.V.

ID: 61676087